People · Operator
Named in public records as an officer, director or promoter · active 2013–2018 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Morphic Holding, Inc. | — | Biotechnology | Series C | $200.6M | $1.5B | 2016 |
| Spero Therapeutics, Inc. | — | Biotechnology | Series C | $92.2M | $150.5M | 2017 |
| CalciMedica Subsidiary, Inc. | — | Biotechnology | Series B | $73.0M | $128.0M | 2013 |
| Zikani Therapeutics, Inc. | — | Pharmaceuticals | Series A | $31.7M | $232.3M | 2018 |
| Pandion Therapeutics, Inc. | — | Biotechnology | Series B | $21.6M | $857.3M | 2018 |
Vikas Goyal at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Vikas Goyal on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jean-Francois Formela | 1 | 17 |
| Kevin Bitterman | 1 | 15 |
| Amir Nashat | 1 | 14 |
| Scott Jackson | 1 | 13 |
| Brian Gallagher | 1 | 11 |
| Alan Crane | 1 | 9 |
| Lawrence Miller | 1 | 8 |
| Carlo Rizzuto | 1 | 7 |
| Bruce Rogers | 1 | 7 |
| Joseph Zakrzewski | 1 | 6 |
| Ramy Farid | 1 | 5 |
| Michael Dunn | 1 | 5 |
| Raj Parekh | 1 | 5 |
| Casper Breum | 1 | 5 |
| Mitchell Mutz | 1 | 5 |
| Robert G. McNeil | 1 | 5 |
| ANKIT MAHADEVIA | 1 | 4 |
| Markus Goebel | 1 | 4 |
| Eric W. Roberts | 1 | 4 |
| Henry Skinner | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.